Clinical Outcome of Patients with Newly Diagnosed Multiple Myeloma in Zagazig University Hospitals | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 169, Volume 87, Issue 1, April 2022, Page 2023-2027 PDF (284.93 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2022.232248 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Haitham Elsheikh; Ayman Fathy; Ahmed Mohamed El Sayed  ; Nahla I. Zidan; Ahmed Embaby
| ||||
| Abstract | ||||
| Background: Multiple myeloma (MM) is a clonal neoplastic plasma cell disorder. With availability of immunomodulators and bortezomib, better response rate and survival outcome have been achieved in newly diagnosed multiple myeloma (NDMM) patients. Objective: To evaluate patients’ response and outcomes to anti-myeloma treatment in a tertiary referral center. Patients and Methods: From September 2020 to February 2022, at Zagazig University Hospitals, Hematology Unit of Internal Medicine Department, our prospective cohort study was conducted on 36 treatment-naïve patients with NDMM. All patients had received anti-myeloma agents and assessed for response and outcome. Results: About the performance status (PS), one quarter of the cases had PS 0 (25%), and 55.6% of the cases were PS 1. Majority of cases responded to treatment (91.7%), while only three cases did not respond. Thirty-three cases showed no progression (91.7%) and three cases only showed progression (8.3%). Ten patients underwent autologous stem cell transplantation (ASCT). After a median follow-up period of 12 months (range 4-18 months); the OS rate was 76.8%, and PFS rate, was 90.7%. Conclusion: This study highlights that by using proper anti-myeloma agents, a reasonable clinical outcome can be achieved in our tertiary center | ||||
| Keywords | ||||
| Anti-myeloma agents; Multiple Myeloma; Outcome | ||||
|
Statistics Article View: 141 PDF Download: 218 |
||||
